Sodium nitroprusside is an excellent agent for lowering blood pressure in hypertensive emergencies, for producing controlled hypotension during anesthesia, and for treating acute myocardial infarction and chronic heart failtse. Toxic effects of this drug have been reported and above-normal cyanide and thiocyanate concentrations have been observed in the blood of a small proportion of subjects receiving nitroprusside. Nitrite, cyanide, and thiocyanate are major decomposition products of nitroprusside, resulting from an in vitro reaction with human blood. On the basis of the conversion mechanism, we suggest that, In the cyanide/thiocyanate cycle, only cyanide is directly responsible for any acute toxicity attributed to sodium nitroprusside. In this work, the extent of cyanide production by erythrocytes in vitro was studied. The rate of detoxif Ication of Cyanide by human liver in vitro was experimentally determined and data from a search for a possible inhibitor of the nitroprusside/hemoglobin reaction are presented. Also, the possible mechanism of the nitroprusside/hemoglobin reaction is discussed. 
anate by the hepatic enzyme thiosulfate sulfurtransferase (rhodanese, EC 2.8.1.1) according to the following reaction (17) , which is practically irreversible: rhodaness Na2S2O3 + HCN -
NaCNS + NaHSO3
About 1% of the thiocyanate generated can be oxidized back to cyanide by a side-reaction catalyzed by the enzyme thiocyanate oxidase (no EC no. assigned), which is present in erythrocytes.
Nitroprusside also reacts rapidly in vitro with oxy-or deoxyhemoglobin to generate biologically inert cyanmethemoglobin and free cyanide. A similar reaction in vitro between thiocyanate and hemoglobin proceeds only in the presence of hydrogen peroxide, and yields methemoglobin, cyanmethemoglobin, sulfate, and free cyanide. However, it is unlikely that enough hydrogen peroxide is present in vivo in human blood, and so we do not consider this reaction to be of great importance in nitroprusside toxicity. Sodium nitroprusside in aqueous or buffer solution in the range of pH from 6 to 8 is quite stable and does not release cyanide, but when it is in contact with various biological fluids, cyanide can be rapidly released. Page et aL (3) found that most of the cyanide activity is associated with erythrocytes and ascribed it to a reaction between nitroprusside and sulfhydryl groups of gluthathione. From our results (Table 1) , we tend to agree with Smith et al. (18) , who demonstrated that nitroprusside reacts rapidly with hemoglobin in vitro and rapidly generates cyanide and cyanmethemoglobin. These conversion mechanisms suggest that any toxicity associated with the use of sodium nitroprusside may be related either to a slow accumulation of thiocyanate via a sulfur transferase reaction or rapid release due to nitroprusside reaction with hemoglobin, or both.
Thiocyanates or cyanates are generally considered to be metabolically inert and not toxic. These ions are well known to be present in normal body fluids. However, some oxidation of sulfur to sulfate can occur, with oxyhemoglobin functioning as a peroxidase, and in this process methemoglobin is generated as well as free cyanide. It can then be suggested that in the thiocyanate/cyanide cycle only cyanide is directly responsible for any acute toxicity attributed to sodium nitroprusside.
This study was undertaken to determine how much cyanide is produced in vitro by erythrocytes from nitroprusside and thiocyanate and its possible inhibition. Because nitroprusside is given by infusion and can therefore be present at the time blood specimens are taken, relatively high concentrations of CN-can be found, possibly complicating the clinical picture in patients receiving this drug. It was also of interest to determine if the rate of detoxification by the liver is sufficient for removal of the quantities of CN-that could be generated from infusions of nitroprusside so that these potential artifacts would be minimized.
Procedures
Cyanide Assay (19) Four milliliters of water and 2 ml of blood containing 2mg of disodium ethylenediaminetetraacetate as anticoagulant (or 2 ml of standard) are pipetted onto the bottom of a 50-nil flask. For each drug run, three separate flasks were used. The first contained 0.1 ml of a 50 mg/liter solution of sodium nitroprusside, the second contained 0. 
30s, to mix the contents, and diffusion was allowed to proceed for 2 h. Then 1 ml was transferred from the diffusion cup (NaCN), into a tube that had been cooled to 4 #{176}C. Chloramine T solution, 0.2 ml, was added and mixed. After 2 mm, 3 ml of pyrazolone reagent was added rapidly and mixed. Color was allowed to develop for 45 mm and then the mixture was extracted with 2 ml of n -butanol. After centrifugation, the absorbance of the butanol (upper) layer was measured at 675 nm vs. n-butanol. The concentration of cyanide was calculated from a calibration curve prepared from dilutions of potassium cyanide. The following drugs and compounds were added separately to the whole blood to give a concentration of 20 mg of each per liter: citric acid, salicylic acid, phenobarbital (5-ethyl-5-phenyl barbituric acid), L-dopa
phenytoin, and pchloromercuric benzoate.
Some of these compounds are metal-chelating agents or enzyme inhibitors, and we wondered whether any of them could inhibit the decomposition of nitroprusside to CN-in whole blood.
Thiocyanate Assay
Thiocyanate was determined in order to follow the change of KCN to thiocyanate. We used the method of Rosenthal et al. (20) , modified for the assay of small homogenate samples. Three milliliters of phosphate buffer (0.11 mol/liter) was placed in a test tube with 0.5 ml of 0.5 mol/liter Na25203 and a 1-ml aliquot of human liver homogenate in physiological saline in concentrations of either 450, 900, or 1800 mg/liter. The reaction was started at room temperature by adding 0.5 ml of neutralized 0.5 mol/liter KCN and stopped after 2 mm by adding 5 ml of trichioroacetic acid solution (100 g/liter) containing 3.6 ml of formaldehyde/water (40/60 by volume) per liter, the purpose of the formaldehyde being to prevent the formation of sulfur from thiosulfate. After 15 mm, the reaction mixture was centrifuged and 1 ml of ferric nitrate was added to 2 ml of the decanted supernatant fluid and the absorbance measured at 550 nm. The same procedure was used for the preparation of the blank, but KCN was added after trichloroacetic acid.
Results and Discussion
The rate at which CN-is formed from nitroprusside in the presence of hemoglobin, with and without known enzyme inhibitors, and the percentage of conversion ofnitroprusside to cyanide are shown in Table 1 .
Human erythrocytes can generate cyanide from nitroprusside rapidly and this property is unaffected by the potential inhibitors we examined. Evidently cyanide should be measured only in samples drawn at least 2 mm after the infusion of nitroprusside has stopped because the normal liver will metabolize the CN-to SCN in that time. Table 2 shows the production of KCNS from KCN in the presence of human liver homogenate, and the concentration of cyanide converted. The plotted results were a linear function; the index of determination of 0.9996 completely confirmed the linearity of thiocyanate production. The data in Table 2 can also be extrapolated to calculate the ability of whole liver to detoxify cyanide in vitro in order to determine the capacity of that organ to handle a load of infused nitroprusside, rapidly converting it to cyanide. In vivo, the liver, which contains the enzyme rhodanese, serves as the main regulatory system of cyanide in the human body. We found that 34.2 mg of CN-per liter of blood can be converted to KSCN in 2 mm by 45 mg of liver-i.e., 1 mg of liver can convert 380 igf liter per minute. Assuming that the liver from a 70-kg human weighs about 1110 g, the whole liver is thus able to convert totally 422 g of CN-per liter to KSCN per minute. The maximum clinically used infusion rate for nitroprusside is 0.56 mg/mm, which is equivalent to about 0.61 mg of potassium cyanide per minute per 5.5 liters of blood. The liver in vitro, therefore, has about 3.8 million times the capacity necessary to convert the CN-formed to CNS. In vivo, the liver may well possess an even greater detoxification capacity, but careful attention should be given to the condition of the liver before this drug is used. When we analyzed blood samples for CN-from 50 patients receiving nitroprusside therapeutically, within 2 mm after the infusion was stopped, we could detect no cyanide (i.e., < 1 mg/liter) in any.
